ALVR241220C2500
- 0.00
- 0.000.00%
AlloVir Newsroom
Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty
Morgan Stanley Maintains AlloVir(ALVR.US) With Sell Rating, Maintains Target Price $0.5
Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)
Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)
Maintaining a Hold: AlloVir's Strategic Uncertainty and Financial Outlook
Analysts' Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)
B of A Securities Downgrades AlloVir to Underperform, Lowers Price Target to $1
AlloVir Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), AlloVir (ALVR) and Bristol-Myers Squibb (BMY)
Hold Rating on AlloVir Following Posoleucel Program Discontinuation and Strategic Shift
Piper Sandler Downgrades AlloVir to Neutral, Lowers Price Target to $1.5
AlloVir Analyst Ratings
AlloVir's Positive Strides in T-Cell Therapy Development and Promising 3Q23 Financial Performance: A Buy Rating Analysis
Piper Sandler Keeps Their Buy Rating on AlloVir (ALVR)
AlloVir Analyst Ratings
Bank of America Securities Initiates a Buy Rating on AlloVir (ALVR)
AlloVir Analyst Ratings
SVB Securities Reaffirms Their Buy Rating on AlloVir (ALVR)
SVB Securities Sticks to Its Buy Rating for AlloVir (ALVR)
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Moderna (MRNA) and AlloVir (ALVR)